Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Astrazeneca Plc (AZN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 83,068,032
  • Shares Outstanding, K 2,531,790
  • Annual Sales, $ 23,002 M
  • Annual Income, $ 3,499 M
  • 36-Month Beta 0.74
  • Price/Sales 3.61
  • Price/Cash Flow 10.63
  • Price/Book 5.39

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.08 +16.77%
on 08/23/17
34.07 -0.35%
on 09/22/17
+4.88 (+16.79%)
since 08/22/17
3-Month
28.43 +19.42%
on 07/27/17
35.33 -3.91%
on 06/26/17
-1.41 (-3.99%)
since 06/22/17
52-Week
25.55 +32.88%
on 12/07/16
35.60 -4.63%
on 06/22/17
-0.33 (-0.96%)
since 09/22/16

Most Recent Stories

More News
Juno Tenders $250M Follow-on Public Offering of Common Stock

Juno Therapeutics (JUNO) launches a proposed follow-on public offering of shares. The company plans to utilize net proceeds from the offering for general corporate purposes.

CELG : 143.89 (+0.08%)
AZN : 33.95 (+3.47%)
ADRO : 10.80 (-1.82%)
JUNO : 45.14 (+8.46%)
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval

Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.

AZN : 33.95 (+3.47%)
MRK : 65.13 (-0.72%)
KITE : 179.30 (-0.04%)
PFE : 35.96 (-0.03%)
Implied Volatility Surging for AstraZeneca (AZN) Stock Options

AstraZeneca (AZN) needs Investors to pay close attention to the stock based on moves in the options market lately.

AZN : 33.95 (+3.47%)
TESARO Ovarian Cancer Drug Zejula Gets Positive CHMP Opinion

TESARO's (TSRO) marketing application for approval of its PARP-inhbitor Zejula as monotherapy for the maintenance treatment of ovarian cancer gets positive CHMP opinion.

HSKA : 89.36 (-0.13%)
AZN : 33.95 (+3.47%)
CLVS : 78.56 (+2.09%)
TSRO : 119.04 (+0.31%)
Oncology Space in Focus this Week on ESMO Presentations

There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.

AZN : 33.95 (+3.47%)
MRK : 65.13 (-0.72%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
BMY : 63.36 (+0.05%)
Bydureon EXSCEL Trial Demonstrates Favorable Cardiovascular (CV) Safety Profile and Fewer CV Events in Patients with Type-2 Diabetes at Wide Range of CV Risk

--Full trial results presented at the annual meeting of the European Association for the Study of Diabetes (EASD) and simultaneously published in the New England Journal of Medicine

AZN : 33.95 (+3.47%)
AstraZeneca Sells Remaining Rights to its Anaesthetics Drugs

AstraZeneca (AZN) recently sold its remaining rights to its anaesthetics medicines to Aspen Group for an upfront consideration of $555 million.

ARLZ : 1.80 (+18.42%)
AZN : 33.95 (+3.47%)
JNJ : 131.39 (-0.27%)
AGN : 204.65 (+0.98%)
Bristol-Myers Reports Positive Results from Melanoma Study

Bristol-Myers Squibb Company (BMY) announced encouraging results from a phase III study, CheckMate -238, on Opdivo.

AZN : 33.95 (+3.47%)
MRK : 65.13 (-0.72%)
PFE : 35.96 (-0.03%)
BMY : 63.36 (+0.05%)
AstraZeneca's Asthma Candidate Shows Promising Results

AstraZeneca's asthma candidate, benralizumab, showed promising results in patients who experience more frequent exacerbations despite being on standard-of-care medicines.

AZN : 33.95 (+3.47%)
REGN : 432.72 (-0.17%)
SNY : 50.34 (+0.78%)
ALXN : 142.82 (-0.07%)
AstraZeneca's Lung Cancer Study Data Promising, Shares Spike

AstraZeneca, (AZN) releases data from a late-stage study on Imfinzi which showed that the new cancer drug led to superior progression-free survival to standard of care in lung cancer patients.

AZN : 33.95 (+3.47%)
MRK : 65.13 (-0.72%)
REGN : 432.72 (-0.17%)
ALXN : 142.82 (-0.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Support & Resistance

2nd Resistance Point 34.30
1st Resistance Point 34.12
Last Price 33.95
1st Support Level 33.72
2nd Support Level 33.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.